Skip to content

Cedar Honey in Oral Lichen Planus

Cedar Honey in Treatment of Oral Lichen Planus: a Randomized Clinical Trial

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01974414
Enrollment
36
Registered
2013-11-01
Start date
2011-09-30
Completion date
2012-12-31
Last updated
2013-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erosive and Atrophic Oral Lichen Planus

Keywords

oral lichen planus, cedar honey, atrophic, erosive, pain, treatment, clinical trial

Brief summary

The study aimed to evaluate the effect of cedar honey in treatment of erosive and atrophic oral lichen planus ( a common oral problem).

Interventions

DRUGorally administered cedar honey

Sponsors

Mashhad University of Medical Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. clinically and histopathologically confirmed oral lichen planus without dysplasia in histopathologic evaluation 2. Severity of pain≥2 (VAS score) 3. Severity of lesions≥2 (tong prasom criteria) 4. absence of any treatment in the last month 5. absence of kidney or liver diseases( due to systemic administration of fluconazole to both groups)

Exclusion criteria

1. evidence of lichenoid reaction in clinical or histopathologic assessment 2. loss of follow up 3. pregnant patients 4. diabetic patients 5. any other mucosal disease 6. any severe systemic disease 7. patients who refuse doctor's advice 8. any unexpected adverse effect of honey

Design outcomes

Primary

MeasureTime frameDescription
severity of lesions4 weeksseverity of lesions due to thong prasom criteria

Secondary

MeasureTime frameDescription
size of lesions4 weeksA sterile caulis was used to measure the maximum diameter of erosive and atrophic lesions and the maximum width perpendicular to the maximum diameter was recorded.

Other

MeasureTime frameDescription
pain of lesions4 weeksPain or burning sensation was assessed by using a visual analog scale (VAS). Patients marked the point from 0(no pain) to 10(extreme pain) representing their present pain perception

Countries

Iran

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026